10月30日-11月1日首届“基因与免疫”国际学术研讨会
文章来源: 点击数: 更新日期:2017-10-26
关于召开首届“基因与免疫”国际学术研讨会通知
    中国是世界上最大的人与动物健康产品的用户,也是人与动物基因与免疫产品研发、创新和生产的理想基地,吸引了世界相关科研机构、企业和人才的目光,世界注视着中国。
    2017年10月30日至11月1日,在安徽农业大学(中国 合肥)生物科技楼举行首届“基因与免疫”国际学术研讨会。
    主题报告专家:牛津大学、泊尔尼大学 Martin F. Bachmann 教授
                  泊尔尼大学 查丽莎 研究员
                  安徽农业大学 陈宏权 教授
                  牛津大学 Mona O. Mohsen 博士
    主办单位:安徽农业大学动物科技学院
              瑞士Bern大学
              安徽地方畜禽遗传资源保护与生物育种重点实验室
              安徽省现代牛羊产业技术体系
 
“基因与免疫”国际学术研讨会议程
时间
内容
地点
10月30日
(星期一)
10:00
报到
科技楼333室
14:00
科技成果物化与创新交流会
科技楼111报告厅
10月31日
(星期二)
9:00
校领导接见,颁发聘书
校会议室
10:00
平台建设交流会
畜牧兽医学科平台
兽医院、SPF室
15:00
学术报告1:基于类病毒体的阿兹海默的疫苗研制与创新(Martin F. Bachmann)
科技楼441报告厅
16:00
学术报告2:纳米抗体研制与应用(Lisha Zha)
科技楼441报告厅
17:00
学术报告3:饮茶与健康:一份来自猪的研究报告(HQ Chen)
科技楼441报告厅
11月1日
(星期三)
9:00
企业交流会
 
15:00
企业交流会

主办联络:安徽农业大学动物科技学院 陈宏权(18056000856
报告人简介:
Martin F. Bachmann
 教授
    马丁.巴赫曼(Martin F. Bachmann),瑞士人,1967年12月15日生,师从诺贝尔生理学奖(1996)获得者辛克纳吉(Rolf M. Zinkernagel),现为牛津大学免疫学教授、伯尔尼大学免疫学教授。主要从事动物免疫遗传学研究及产品开发。
1. 达到临床开发的候选基因药物(瑞士医药集团塞托斯生物技术公司)
(1)Proof-of-Concept for immunogenicity; Phase I completed
(2)Immunodrug for treatment of smoking addiction; Phase I completed, 
     Phase II reaches proof-of-concept.
(3)Immunodrug for the treatment of allergies; Phase I completed clinical proof-of-concept for rhinitis has been reached in phase IIa and phase IIb studies
(4)Immunodrug for the treatment of asthma. Clinical proof-of-concept has been reached in phase IIa study
(5)Immunodrug against house-dust-mite allergy; Phase I completed, Phase II reaches proof-of-concept.
(6)Immunodrug against hypertension; preclinical research completed; Proof-of-concept reached in Phase 2a study. Phase IIb study ongoing
(7)Immunodrug against Melanoma; preclinical research completed; Several phase I/II completed. The drug candidate has been shown to induce good T cell responses
(8)Immunodrug against Alzheimer`s disease (in collaboration with Novartis); preclinical research completed; several Phase II studies are ongoing
(9)Immunodrug against type II diabetes.
2. 在影响因子5.0以上杂志发表论文180余篇,总影响因子超过2000,其中在Nature、Science和Cell杂志发表的研究论文:
Bachmann, MF, 等. 1993. The influence of antigen organization on B cell responsiveness. Science 262:1448-1451. Impact: 31
Bachmann, MF,等. 1997. The role of antibody concentration and avidity in antiviral protection. Science 276:2024-2027. Impact: 31
Kundig, T.M., MF Bachmann, 等. 1995. Fibroblasts as efficient antigen-presenting cells in lymphoid organs. Science 268:1343-1347. Impact: 31
Kopf, M., G. Le Gros, M.Bachmann, 等. 1993. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 362:245-248. Impact: 38.8
Kundig, T.M., H. Schorle, M.F. Bachmann, 等. 1993. Immune responses in interleukin-2-deficient mice. Science 262:1059- 1061. Impact: 31
Holtschke, T., J. Lohler, Y. Kanno, T. Fehr, N. Giese, F. Rosenbauer, J. Lou, K.P. Knobeloch, L. Gabriele, J.F. Waring, M.F. Bachmann, 等. 1996. Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell 87:307-317. Impact: 32
Fehr, T., H.Y. Naim, M.F. Bachmann, 等. 1998. T-cell independent IgM and enduring protective IgG antibodies induced by chimeric measles viruses. Nat Med 4:945-948. Impact: 22.8
Koller, D., C. Ruedl, M. Loetscher, J. Vlach, S. Oehen, K. Oertle, M. Schirinzi, E. Deneuve, R. Moser, M. Kopf, J.E. Bailey, W. Renner, and M.F. Bachmann. 2001. A high-throughput alphavirus-based expression cloning system for mammalian cells. Nat Biotechnol 19:851-855. Impact: 32.4
Kopf, M., B. Abel, A. Gallimore, M. Carroll, and M.F. Bachmann. 2002. Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med 8:373-378. Impact: 22.8
Mueller S.N., K.A. Hosiawa-Meagher,B.T. Konieczny, B.M. Sullivan, M.F. Bachmann, 等. 2007. Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science 317:670-4. Impact: 31
Araki, K., A.P. Turner, V.O. Shaffer, S. Gangappa, S.A. Keller, M.F. Bachmann, 等. 2009. mTOR regulates memory CD8 T-cell differentiation. Nature 460:108-112. Impact: 38.6
 
 
Lisha Zha
Bern University Hospital (Inselspital), SWITZERLAND
瑞士双峰会联合创办人及会议主持人
LIfeScience公司CEO
Affinibody LifeScience公司CEO
Inselspital 医院高级研究员
Post Doctor in Immunology and cancer  
Research Field: Vaccine development against melanoma
Ph.D in Molecular Biology, Helmholtz Centre for Infection Research, GERMANY
 
 
 Mona O. Mohsen
牛津大学博士
从事免疫学、癌症研究
主要开展:
Virus like particles based vaccines
Testing MCT and DOPS adjuvants in combination with VLPs-based vaccines in murine melanoma models
Developing therapeutic personalised melanoma VLPs based vaccine
Copyright 2014 © 安徽农业大学 All Rights Reserve

地址:安徽省合肥市长江西路130号| 邮编:230036 | 电话号码:0551-65786411/65786203 | 联系邮箱:xww@ahau.edu.cn,fgc@ahau.edu.cn